BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
BioAge Labs, Inc. is holding its 2026 virtual annual stockholder meeting on June 10, 2026 at 12:00 p.m. Eastern Time. Stockholders of record as of April 16, 2026, when 44,397,817 common shares were outstanding, may vote online, by telephone, or by mail.
Stockholders will vote on electing three Class II directors to three-year terms and on ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board unanimously recommends voting FOR both proposals.
The company describes its corporate governance structure, committee composition, director independence and compensation, and executive pay. In 2025, CEO Kristen Fortney received a $600,000 salary, a $330,000 cash bonus, and option awards valued at $1,941,390. BioAge also highlights its emerging growth and smaller reporting company status and recently adopted clawback and updated insider trading policies.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and then sold the resulting shares. On April 1, 2026, he exercised options covering 8,820 shares of common stock at strike prices of $4.11 and $6.57 per share.
The same day, he sold 8,820 shares of common stock at $17.81 per share in an open-market transaction, leaving 0 shares of common stock held directly after the sale. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.
BIOA Rule 144 notice: The filing lists proposed and recent sales of Common stock under Rule 144. It shows three reported sales by Paul Rubin of 7,433 shares each on 01/02/2026, 02/02/2026, and 03/02/2026 with dollar proceeds reported for each sale. The filing also lists securities to be sold on 04/01/2026 connected to options granted on 07/01/2020 and 05/29/2022.
BioAge Labs, Inc. filed a shelf registration statement on March 24, 2026 to register an unspecified aggregate amount of securities for future issuance under Form S-3.
The prospectus permits offers of common stock, preferred stock, debt securities, warrants, subscription rights and units in one or more offerings from time to time after effectiveness. The filing states there is no limit on the aggregate amount of securities registered and that terms, prices and amounts will be set in prospectus supplements. The prospectus references 37,386,908 shares of common stock outstanding as of December 31, 2025, outstanding stock options to purchase 7,914,058 shares with a weighted-average exercise price of $7.74, and discloses a last reported Nasdaq price of $18.63 per share on March 23, 2026.
BioAge Labs, Inc. reports 2025 results showing increased R&D investment and a strong cash position to support its cardiometabolic pipeline. The company generated $8.995M in collaboration revenue, primarily from its Novartis agreement, and recorded a net loss of $80.6M on operating expenses of $101.8M.
Research and development spending rose to $74.0M, driven by progress on lead NLRP3 inhibitor BGE-102, new apelin receptor APJ obesity programs, and Novartis-funded discovery work. General and administrative costs increased to $27.8M, reflecting public-company expenses, legal fees, and higher stock-based compensation.
As of December 31, 2025, BioAge held $285.1M in cash, cash equivalents and marketable securities and had $2.0M outstanding under its term loan. Management believes this liquidity can fund planned operations through 2029 while advancing BGE-102 into Phase 2a cardiometabolic and ophthalmology trials and preparing APJ agonist INDs.
BioAge Labs reported full-year 2025 results showing its transition into a later-stage clinical company. Collaboration revenue reached $9.0 million, driven by work under a multi-year Novartis research collaboration, while research and development expenses rose to $73.9 million and general and administrative expenses to $27.8 million as the pipeline and public-company infrastructure expanded. Net loss was $80.6 million, or $2.24 per share, compared with a $71.1 million loss in 2024. The company ended 2025 with $285.1 million in cash, cash equivalents, and marketable securities and estimates this will fund operations through 2029. Clinically, lead NLRP3 inhibitor BGE-102 delivered positive interim Phase 1 data, including an 86% median hsCRP reduction at 120 mg once daily and strong IL‑1β suppression, supporting Phase 2a cardiovascular risk and ophthalmology trials beginning in 2026. BioAge also advanced its APJ agonist programs toward an initial IND by late 2026 and strengthened its balance sheet via a $132.3 million upsized follow-on equity offering.
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and sold the resulting shares. On March 2, 2026, he exercised options for a total of 7,433 shares of common stock at exercise prices of $4.11 and $6.57 per share. He then sold all 7,433 common shares in an open-market transaction at $20.30 per share, leaving him with zero directly held common shares after the sale. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024, and the options exercised were fully vested, with vesting beginning on April 1, 2022 and the award becoming fully vested on May 11, 2024.
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein reported exercising stock options and receiving common shares. On March 1, 2026, he exercised options for 3,542 shares of common stock at $4.38 per share through an option conversion.
After these transactions, he held 33,033 shares of common stock directly and 159,375 stock options directly. The option award vests in equal monthly installments over 48 months, with vesting that began on February 1, 2025, subject to his continued service.
Paul Rubin reported multiple sales of common stock on Form 144. The filings list sales including 68,897 shares on 12/04/2025, 18,000 shares on 12/09/2025, 7,433 shares on 01/02/2026, and 7,433 shares on 02/02/2026. The notices identify Fidelity Brokerage Services LLC as a broker on 03/02/2026 for additional option-related sales.